| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba045776bcd32d32e3100da8dfce4e28 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-12 |
| filingDate |
1996-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a802ab3c5a15904eb0aba074e8685457
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32b2bc67ab10904587980cc62dca19d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba03de559978a8064a606c16dd1c9fb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61bb57824e5a3173b10972be8b375d65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e66e88e93c9f175a0fcb951c9cfe989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9284b5e0b9e9def6ea863ded49ab3f3f |
| publicationDate |
1998-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-30998-A3 |
| titleOfInvention |
A pharmaceutical composition comprising 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors |
| abstract |
Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R<1> is for example H and further values as defined in the specification; R<2> is for example H and further values as defined in the specification; R<3> is for example H or a substituent having values as defined in the specification; p is 0-3 in which R<3> values can be the same or different; L is a linking moiety for example -CO-NH2- and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a -S-S- dimer thereof when R<2>=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy. |
| priorityDate |
1995-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |